Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis

This publication has 29 references indexed in Scilit:

• Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group
  Published by American Medical Association (AMA) ,1995
• Sequential Anti-core Glycolipid Immunoglobulin Antibody Activities in Patients With and Without Septic Shock and Their Relation to Outcome
  Annals of Surgery, 1993
• Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide.
  The Journal of Experimental Medicine, 1993
• Treatment of Severe Infectious Purpura in Children with Human Plasma from Donors Immunized with Escherichia coli J5: A Prospective Double-Blind Study
  The Journal of Infectious Diseases, 1992
• Lipid IVA inhibits synthesis and release of tumor necrosis factor induced by lipopolysaccharide in human whole blood ex vivo.
  The Journal of Experimental Medicine, 1990
• Oral Ciprofloxacin and a Monoclonal Antibody to Lipopolysaccharide Protect Leukopenic Rats from Lethal Infection with Pseudomonas aeruginosa
  The Journal of Infectious Diseases, 1989
• Preliminary Study on Treatment of Septic Shock Patients with Antilipopolysaccharide IgG from Blood Donors
  Scandinavian Journal of Infectious Diseases, 1989
• Characterization of the Human Antibody Response to an Escherichia coli O111:B4 (J5) Vaccine
  The Journal of Infectious Diseases, 1988
• Treatment of Gram-Negative Septic Shock with Human IgG Antibody to Escherichia coli J5: A Prospective, Double-Blind, Randomized Trial
  The Journal of Infectious Diseases, 1988
• Treatment of Gram-Negative Bacteremia and Shock with Human Antiserum to a MutantEscherichia coli
  New England Journal of Medicine, 1982